On Thursday, Tilray Medical, a division of medical marijuana giant Tilray Brands, Inc. (NASDAQ:TLRY), announced the final ...

Q1 was way below expectations, and the outlook has been diminished. The stock looks expensive to peers. Find out why TLRY ...

Zuanic & Associates rates Tilray "Neutral," noting long-term potential but near-term uncertainties, despite cannabis growth ...

"Men's Health on Tap" is a conversational podcast that covers a wide range of topics, including mental health and wellness, ...

Cannabis stocks plunge as Florida's legalization fails and GOP Senate control tempers expectations for industry growth.

This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received ...

Tilray Brands Inc. is trying to trick investors for a second straight year into increasing its share limit, according to a lawsuit against the Canadian cannabis company.

Tilray and Anheuser-Busch reached an all-cash deal for the former to take ownership of a handful of popular brands. The cannabis company announced the move on Monday. The legalization of marijuana ...

Tilray, like most companies in the cannabis industry, has performed terribly in recent years. Positive legal and regulatory changes might help turn things around. However, there's still too much ...

Tilray's Q1 revenue missed estimates by $21 million, showing 13% year-over-year growth driven by beverage acquisitions, while cannabis revenue declined nearly 13%. The company reported a larger ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...